RxDoctor Payments Data

Stephen Lazaroff, DPM

Podiatrist · Waterbury, CTNPI 1588084362

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Gramercy Extremity Orthopedics LLC at 35.3% of the total. Reporting peaked in 2019 at $925 and has fallen 65.2% since, to $322 in 2025.

$3,424in general payments, 2019–2025

Across 48 payments — averaging $71.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gramercy Extremity Orthopedics LLC$1K
  • Smith+Nephew$855
  • Celularity Inc.$259
  • Organogenesis Inc.$185
  • Orthofix Medical, Inc.$178
  • Gotham Surgical Solutions & Devices, Inc.$144
  • plus $594 from 7 others
$50,000in ownership & investment interests, 2019–2025

Across 7 payments — averaging $7142.86 each. An ownership or investment interest held by the physician or an immediate family member.

  • Gramercy Extremity Orthopedics LLC$50K

What the payments were for

  • Food & beverage$3,424100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,424 in reported general payments places this provider in the 85th percentile of 119 podiatrist providers in Connecticut.

See all podiatrist providers in Connecticut

Medicare billing

Part B allowed, 2024
$660,709
Medicare patients
135
Services billed
2,689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole14$17,163
Clotrimazole13$162
Oxycodone Hcl29$122
Doxycycline Hyclate17$110
Mupirocin18$106
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen31$103
Meloxicam21$71

Paid to pharmacies, not to this prescriber.

Other podiatrist in Waterbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →